The Vicious Cycle

Daniel George | March 01, 2019

Contrary to your initial reaction, the title for this blog is not an illusion to that ingenious remake of the stationary bike. The vicious cycle I am referring to is instead the positive feedback loop between prostate adenocarcinoma cells and osteocytes resulting in growth of both cellular compartments and ultimately the formation of bone metastases.  While metastases can occur in many organ systems, there is a disproportionate frequency and number of bone metastases in prostate cancer, which drive much of the morbidity of this disease. For many patients, bone metastases are the only site of disease spread, and the vicious cycle is likely the culprit for this pattern. 

READ MORE PREVIOUS ARTICLES

Daniel George

Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine and leads the Duke Prostate and Urologic Cancer Center. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. Daniel George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006.

Videos
State-of-the-industry video lectures by leading urology experts
Library Resources
Evidence based monographs by experts to define and guide clinical practice
Written by Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc
Prostate cancer exhibits a wide spectrum of disease behaviour. Despite the majority of cases presenting with relatively indolent biologic behaviour, prostate cancer remains the second leading cause of cancer-related death in the United States, behind only lung cancer.
Conference Coverage
Recent data from conferences worldwide
Presented by Silke Gillessen, MD
San Francisco, CA (UroToday.com) Silke Gillessen, MD presented a study comparing two different dosing frequencies of Denusomab in patients with castration-resistant prostate cancer, and evaluating the rate of hypocalcemia in these two treatment options.
Presented by Matthew R. Smith, MD, Ph.D.
Munich, Germany (UroToday.com) Radium-223 is an alpha emitter which selectively treats bone metastases with alpha radiation1. In a recent GU ASCO oral presentation, a radium-223 pharmacodynamic study demonstrated
Presented by Matthew R. Smith, MD, Ph.D.
Munich, Germany (UroToday.com) As has been the trend in management of advanced solid malignancies, there has been increasing interest 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe